Aventera Antibodies
Aventera Antibodies is developing a first-in-class precision immunotherapy for invasive Group A Streptococcal (iGAS) infections, a condition with high mortality despite current antibiotic-based care. The company isolates protective antibodies from human survivors of severe streptococcal infections and enhances them through proprietary precision engineering to achieve broad strain coverage and potent immune-mediated killing. Designed to pair with routine rapid Strep-A tests, the therapy aims to enable early intervention before life-threatening disease develops, with first-in-human studies planned for 2028.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Invasive Group A Streptococcal (iGAS) infections are surging, with high mortality rates despite current standard-of-care treatments that rely heavily on antibiotics. Escalating antimicrobial resistance and stagnant clinical outcomes underscore the critical limitations of existing approaches.
Solution
Aventera is developing a first-in-class precision immunotherapy against iGAS disease, bringing precision medicine to this severe and growing medical problem. The company has isolated potent protective antibodies from individuals who have successfully overcome severe streptococcal infections, then enhanced these natural antibodies through proprietary precision engineering. The lead candidate offers strong immune-mediated killing of Group A Streptococcus alongside broad strain coverage. Designed to be paired with routine rapid Strep-A tests, the therapy enables clinicians to intervene during a critical window—eliminating the bacteria before it triggers severe, life-threatening disease, thereby reducing mortality.
Target Audience
Primary customers are clinicians treating patients with invasive Group A Streptococcal infections, particularly those in hospital and acute-care settings where early intervention is critical, as well as healthcare systems seeking to reduce iGAS mortality.
Features
- Lead candidate derived from protective antibodies isolated from human survivors of severe streptococcal infections
- Proprietary precision engineering enhances the natural antibody into a highly effective therapeutic
- Broad strain coverage with potent immune-mediated killing of Group A Streptococcus through careful epitope selection
- Designed for combination with routine rapid Strep-A diagnostic tests for early intervention
- Preclinical-stage pipeline advancing toward first-in-human studies planned for 2028